CanCure LLC

CanCure is an anticancer drug development startup venture developing antibodies that can revitalize patients own natural immune function to fight cancer. CanCure leading product CuraB-10 is ready to enter into clinical trials.

CanCure and its core technology was invented by Dr. Jennifer Wu, currently a Professor at the Medical University of South Carolina (MUSC) and Hollings Cancer Center.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.cancurellc.com
Founded2013
Disease Focus
Development Stage
STOCK CODENon Listed
Address
1531 NE 172nd St., WA 98155
Shoreline
United States
Email
Contact Number
+1 206 353-7538

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://in.linkedin.com/company/cancure-llc” connections=”true” suffix=””]

CanCures mAbs act on the immune modulators MICA and MICB, which are shed from tumor cells in soluble, immunosuppressive forms that bind and down-regulate NKG2D receptors on NK and other immune cells. When functional, NKG2D receptors activate the cells to trigger cytotoxicity and send co-stimulatory signals to augment the immune response and fight cancer or infection.

In Sep 2016, CanCure received NIH/NCI STTR Phase I small business award to advance the CanCure leading first-in-class cancer immunotherapeutic leading antibody CuraB-10 for clinical application.